Answers are grounded in this paper and cite their sources.
Bevacizumab improved progression-free survival in women with ovarian cancer. The benefits with respect to both progression-free and overall survival were greater among those at high risk for disease progression. (Funded by Roche and others; ICON7 Controlled-Trials.com number, ISRCTN91273375.).
No takes yet. Share an insight, caveat, or question.
Perren et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: